Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 52 42 14 69
Acute Coronary Syndrome 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:326
NCIt 47 C34738
SNOMED-CT 64 52674009
UMLS 69 C0022116

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to myocardial infarction and peripheral artery disease, and has symptoms including anoxemia, polydipsia and muscle weakness. An important gene associated with Ischemia is EGR1 (Early Growth Response 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Allograft rejection. The drugs Aspirin and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and endothelial, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 72 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen and... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 517)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 31.9 ACE CASP3 CXCL12 GJA1 MPO NOS3
2 peripheral artery disease 30.9 ACE NOS3 PON1 VEGFA
3 renal fibrosis 30.6 ACE CXCL12 NOS3 VEGFA
4 hypertonia 30.2 NOS3 VEGFA
5 malaria 28.8 CASP3 EPO HMOX1 HSPA4 VEGFA
6 transient cerebral ischemia 12.2
7 brain ischemia 12.2
8 critical limb ischemia 12.2
9 retinal ischemia 12.0
10 limb ischemia 12.0
11 mesenteric artery ischemia 11.9
12 chronic myocardial ischemia 11.9
13 cerebral hypoxia 11.2
14 hypoxia 11.1
15 coronary artery disease 11.1
16 vascular disease 11.1
17 vertebrobasilar insufficiency 11.1
18 myocardial stunning 11.0
19 intermittent claudication 11.0
20 temporal arteritis 10.9
21 central retinal vein occlusion 10.9
22 calciphylaxis 10.9
23 cerebral atherosclerosis 10.9
24 clitoris cancer 10.9 ACE EPO NOS3
25 diffuse large b-cell lymphoma 10.9 ACE EPO SOD2 VEGFA
26 lethal congenital contractural syndrome 2 10.9 EPO NOS3 VEGFA
27 carotid body cancer 10.8 ACE APP PON1 VEGFA
28 cerebritis 10.8
29 lichen planus 10.8 EPO NOS3 VEGFA
30 retinitis pigmentosa 10.8 CASP3 CXCL12 VEGFA
31 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.8 ACE NOS3 VEGFA
32 hepatocellular adenoma 10.8 ACE MPO NOS3
33 citrullinemia, adult-onset type ii 10.8 ACE NOS3 PON1 VEGFA
34 focal dystonia 10.8 ACE NOS3 VEGFA
35 arterial calcification, generalized, of infancy, 1 10.8
36 sturge-weber syndrome, somatic, mosaic 10.8
37 legg-calve-perthes disease 10.8
38 arterial calcification, generalized, of infancy, 2 10.8
39 nonarteritic anterior ischemic optic neuropathy 10.8
40 lateral medullary syndrome 10.8
41 mini stroke 10.8
42 pontocerebellar hypoplasia type 2c 10.8 CASP3 GJA1 HSPA4
43 acute vascular insufficiency of intestine 10.7
44 chronic intestinal vascular insufficiency 10.7
45 lymphadenitis 10.7 ACE HMOX1 NOS3
46 prostate carcinoma in situ 10.7 APP CASP3 CDK5 VEGFA
47 periampullary adenoma 10.7 ACE NOS3 VEGFA
48 ovarian cystadenocarcinoma 10.7 APP CASP3 HMOX1
49 pyelonephritis 10.6 ACE HMOX1 NOS3
50 charcot-marie-tooth disease, type 4c 10.6 EPO HSPA4

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


anoxemia, polydipsia, muscle weakness, angina pectoris

MGI Mouse Phenotypes related to Ischemia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 ACE ADORA3 APP CASP3 CAV1 CDK5
2 cellular MP:0005384 10.44 CAV1 CXCL12 EGR1 EPO GJA1 HMOX1
3 behavior/neurological MP:0005386 10.43 EGR1 GJA1 HMOX1 HSPA4 HYOU1 NOS3
4 cardiovascular system MP:0005385 10.42 EPO GJA1 HMOX1 MAP3K5 MPO NOS3
5 hematopoietic system MP:0005397 10.39 ACE ADORA3 APP CASP3 CAV1 CXCL12
6 immune system MP:0005387 10.32 ACE ADORA3 APP CASP3 CAV1 CXCL12
7 mortality/aging MP:0010768 10.31 NOS3 SOD2 VEGFA ACE APP CASP3
8 endocrine/exocrine gland MP:0005379 10.22 PRKAA2 VEGFA ACE CASP3 CAV1 EGR1
9 integument MP:0010771 10.16 ADORA3 APP CASP3 CAV1 CDK5 EGR1
10 muscle MP:0005369 10.15 APP CASP3 CAV1 CXCL12 EPO GJA1
11 nervous system MP:0003631 10.13 APP CASP3 CAV1 CDK5 CXCL12 EGR1
12 liver/biliary system MP:0005370 10.09 EGR1 EPO HMOX1 NOS3 SOD2 VEGFA
13 renal/urinary system MP:0005367 9.81 ACE ADORA3 CASP3 CAV1 HMOX1 NOS3
14 no phenotypic analysis MP:0003012 9.8 ADORA3 APP CASP3 CDK5 CXCL12 GJA1
15 reproductive system MP:0005389 9.73 HMOX1 HSPA4 NOS3 SOD2 VEGFA GJA1
16 respiratory system MP:0005388 9.32 ADORA3 CASP3 CAV1 CDK5 EGR1 EPO

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1202)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
2
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
3
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72956-09-3 2585
4
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 28523-86-6 5206
5
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2216-51-5 16666
6
Capsaicin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 404-86-4 1548943
7
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
8
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
9 Nadroparin Approved Phase 4 9041-08-1
10
Benzocaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
11
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1 7440-66-6 32051 23994
12
Nimodipine Approved Phase 4,Phase 2 66085-59-4 4497
13
Atenolol Approved Phase 4,Phase 3,Phase 2 29122-68-7 2249
14
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
15
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 142387-99-3, 95635-55-5 56959
16
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
17
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55-56-1 9552079 2713
18
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
20
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
21
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55142-85-3 5472
22
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 6167 2833
23
Abciximab Approved Phase 4,Phase 3,Phase 2 143653-53-6
24
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
25
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
27
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
28
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 124-94-7 31307
29
Adenosine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-61-7 60961
30
Nicorandil Approved Phase 4,Phase 3 65141-46-0 47528
31
Nicardipine Approved Phase 4,Phase 3,Early Phase 1 55985-32-5 4474
32
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
33
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
34
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
35
Varenicline Approved, Investigational Phase 4,Phase 3 249296-44-4 5310966
36
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
37
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
38
Cilostazol Approved Phase 4,Phase 3,Phase 2 73963-72-1 2754
39
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
40
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1 7440-47-3 27668
41
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
42
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1 81-81-2 6691 54678486
43
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
44
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
45
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
46
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 64-17-5 702
47
Phenprocoumon Approved Phase 4,Phase 3 435-97-2 9908 54680692
48
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
49
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
50
Metronidazole Approved Phase 4,Phase 1 443-48-1 4173

Interventional clinical trials:

(show top 50) (show all 9861)

id Name Status NCT ID Phase Drugs
1 Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Unknown status NCT01104441 Phase 4
2 Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia Unknown status NCT00403780 Phase 4 pregabalin;placebo
3 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
4 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
5 Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion Unknown status NCT00526695 Phase 4 Sevoflurane (Preconditioning)
6 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II) Unknown status NCT01173094 Phase 4
7 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
8 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
9 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
10 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) Unknown status NCT01171703 Phase 4
11 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
12 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
13 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
14 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
15 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
16 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
17 Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke Unknown status NCT02176395 Phase 4 Danhong injection;placebo
18 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
19 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
20 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
21 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
22 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
23 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
24 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
25 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
26 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
27 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
28 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4 Optimal medical therapy
29 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
30 Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity Unknown status NCT00326690 Phase 4
31 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
32 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
33 Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
34 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
35 Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Unknown status NCT01342822 Phase 4
36 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
37 Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population Unknown status NCT01663805 Phase 4 Everolimus
38 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
39 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
40 Effect of Conditioning on Myocardial Damage in STEMI Unknown status NCT02158468 Phase 4
41 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
42 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status NCT00325793 Phase 4 Nicardipine
43 Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI Unknown status NCT01033058 Phase 4 atorvastatin;atorvastatin
44 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
45 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
46 Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis Unknown status NCT01500668 Phase 4 Botox;Placebo
47 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
48 Anticoagulant Treatments and Percutaneous Coronary Angioplasty Unknown status NCT00669149 Phase 4 clopidogrel + aspirin;heparin + clopidogrel + aspirin;enoxaparin + clopidogrel + aspirin;bivalirudin + clopidogrel + aspirin
49 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
50 Optical Coherence Tomography for Drug Eluting Stent Safety Unknown status NCT00693030 Phase 4

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

39
Heart, Brain, Endothelial, Bone, Testes, Kidney, Spinal Cord

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 6326)
id Title Authors Year
1
Effects of longa89term posta89ischemic treadmill exercise on gliosis in the aged gerbil hippocampus induced by transient cerebral ischemia. ( 28440411 )
2017
2
Shifting Perceptions of Risk and Reward: Use of Anticoagulation in Patients With Acute Brain Ischemia and Atrial Fibrillation: Nine-Year Data From a National Acute Stroke Registry (National Acute Stroke Israeli Survey [NASIS]). ( 28258255 )
2017
3
Phonomyography as a non-invasive continuous monitoring technique for muscle ischemia in an experimental model of acute compartment syndrome. ( 28867642 )
2017
4
Transient cerebral ischemia induces albumin expression in microglia only in the CA1 region of the gerbil hippocampus. ( 28586018 )
2017
5
The Effect of Velvet Antler Proteins on Cardiac Microvascular Endothelial Cells Challenged with Ischemia-Hypoxia. ( 28936174 )
2017
6
CD74-immunoreactive activated M1 microglia are shown late in the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 28487994 )
2017
7
Diagnostic and Prognostic Relevance of Magnetic Resonance Imaging and Electrophysiological Findings in Acute Spinal Ischemia. ( 28089563 )
2017
8
Semi-synthetic sapogenin exerts neuroprotective effects by skewing the brain ischemia reperfusion transcriptome towards inflammatory resolution. ( 28390980 )
2017
9
Biodegradable Carriers for Delivery of VEGF Plasmid DNA for the Treatment of Critical Limb Ischemia. ( 28848442 )
2017
10
Neuroprotective effects of ischemic preconditioning on hippocampal CA1 pyramidal neurons through maintaining calbindin D28k immunoreactivity following subsequent transient cerebral ischemia. ( 28761424 )
2017
11
OCT Angiography: Assessment of Retinal Ischemia in Susac's Syndrome. ( 28613358 )
2017
12
Limb Ischemia after Heart Transplantation: An Unusual Case of Tissue Embolism. ( 28828026 )
2017
13
Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. ( 28636406 )
2017
14
Neuroprotective effects of a novel peptide, FK18, under oxygen-glucose deprivation in SH-SY5Y cells and retinal ischemia in ratsA viaA the Akt pathway. ( 28257830 )
2017
15
The role of SUMOylation in cerebral hypoxia and ischemia. ( 28323006 )
2017
16
The role of neuroimaging in elucidating the pathophysiology of cerebral ischemia. ( 28947375 )
2017
17
Giant Fecalith Causing Near Intestinal Obstruction and Rectal Ischemia. ( 28611554 )
2017
18
Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study. ( 28569655 )
2017
19
Fetal Growth Restriction Induced by Transient Uterine Ischemia-Reperfusion: Differential Responses in Different Mouse Strains. ( 28946817 )
2017
20
Clues to Discordance and Dissimilarity Between Coronary Stenosis and Lesion-Specific Ischemia. ( 28687541 )
2017
21
Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products. ( 27914820 )
2017
22
Transplantation of lineage-negative stem cells in pterygopalatine artery ligation induced retinal ischemia-reperfusion injury in mice. ( 28210901 )
2017
23
Reverse electron transfer results in a loss of flavin from mitochondrial complex I: Potential mechanism for brain ischemia reperfusion injury. ( 28914132 )
2017
24
Neuroprotective effects of Kukoamine A against cerebral ischemia via antioxidant and inactivation of apoptosis pathway. ( 28088348 )
2017
25
Combined l-citrulline and glutathione administration prevents neuronal cell death following transient brain ischemia. ( 28315310 )
2017
26
Transient Global Cerebral Ischemia Induces RNF213, a Moyamoya Disease Susceptibility Gene, in Vulnerable Neurons of the Rat Hippocampus CA1 Subregion and Ischemic Cortex. ( 28734662 )
2017
27
Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement. ( 28920529 )
2017
28
Overexpression of Heme Oxygenase-1 in Mesenchymal Stem Cells Augments Their Protection on Retinal Cells In Vitro and Attenuates Retinal Ischemia/Reperfusion Injury In Vivo against Oxidative Stress. ( 28255307 )
2017
29
Effects of Deltorphin II and Its Retroenantio Analog on Cardiac Tolerance to Ischemia and Reperfusion. ( 28091919 )
2017
30
The Effect of Charcot Neuroarthropathy on Limb Preservation in Diabetic Patients with Foot Wound and Critical Limb Ischemia after Balloon Angioplasty. ( 28951878 )
2017
31
Curcumin reverses neurochemical, histological and immuno-histochemical alterations in the model of global brain ischemia. ( 28053883 )
2017
32
Catheter directed thrombolysis is not limited to acute limb ischemia treatment- the experience from vascular surgery division. ( 28849898 )
2017
33
Neutralizing anti-interleukin-1I^ antibodies reduce ischemia-related interleukin-1I^ transport across the blood-brain barrier in fetal sheep. ( 28089577 )
2017
34
Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. ( 28642575 )
2017
35
Longitudinal Assessments of Normal and Perilesional Tissues in Focal Brain Ischemia and Partial Optic Nerve Injury with Manganese-enhanced MRI. ( 28230106 )
2017
36
Mitochondrial-Targeted Antioxidant Maintains Blood Flow, Mitochondrial Function, and Redox Balance in Old Mice Following Prolonged Limb Ischemia. ( 28869535 )
2017
37
Pharmacologic Protection of Mitochondrial DNA Integrity May Afford a New Strategy for Suppressing Lung Ischemia-Reperfusion Injury. ( 28945469 )
2017
38
Optic Nerve Degeneration after Retinal Ischemia/Reperfusion in a Rodent Model. ( 28878627 )
2017
39
Effects of ischemic preconditioning on PDGF-BB expression in the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 28627606 )
2017
40
Acute mesenteric ischemia and hepatic infarction after treatment of ectopic Cushing's syndrome. ( 28480039 )
2017
41
Myeloid differentiation protein 2-dependent mechanisms in retinal ischemia-reperfusion injury. ( 28063877 )
2017
42
Physical Exercise Improves Cognitive Outcomes in 2 Models of Transient Cerebral Ischemia. ( 28663509 )
2017
43
Complement inhibition attenuates acute kidney injury after ischemia-reperfusion and limits progression to renal fibrosis in mice. ( 28832655 )
2017
44
Hyperglycemia aggravates decreases of PEA-15 and its two phosphorylated forms in cerebral ischemia. ( 28216548 )
2017
45
LOTUS overexpression accelerates neuronal plasticity after focal brain ischemia in mice. ( 28880879 )
2017
46
Association of arterial calcification with chronic limb ischemia in patients with peripheral artery disease. ( 28870682 )
2017
47
Blood free Radicals Concentration Determined by Electron Paramagnetic Resonance Spectroscopy and Delayed Cerebral Ischemia Occurrence in Patients with Aneurysmal Subarachnoid Hemorrhage. ( 28948569 )
2017
48
Prea89treatment with ChrysanthemumA indicum LinnAc extract protects pyramidal neurons from transient cerebral ischemia via increasing antioxidants in the gerbil hippocampal CA1 region. ( 28534982 )
2017
49
The hypoxanthine-xanthine oxidase axis is not involved in the initial phase of clinical transplantation-related ischemia-reperfusion injury. ( 28031169 )
2017
50
Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease. ( 28528579 )
2017

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 CASP3 CAV1 CXCL12 HSPA4 MAP3K5 NOS3
2
Show member pathways
12.69 CASP3 CAV1 CXCL12 HSPA4 VEGFA
3
Show member pathways
12.6 CASP3 CDK5 EGR1 MAP3K5 NOS3 VEGFA
4
Show member pathways
12.32 ADORA3 CASP3 CAV1 CXCL12 EGR1 EPO
5 12.02 CASP3 EGR1 GJA1 VEGFA
6 11.94 CASP3 CDK5 EGR1 PRKAA2
7
Show member pathways
11.7 CAV1 NOS3 VEGFA
8 11.66 CASP3 EGR1 NOS3 VEGFA
9
Show member pathways
11.63 CASP3 CXCL12 MAP3K5
10 11.62 EPO HMOX1 NOS3 VEGFA
11 11.52 CASP3 GJA1 MAP3K5 NOS3 PRKAA2
12 11.43 EPO NOS3 VEGFA
13 11.37 CXCL12 EPO HMOX1 VEGFA
14
Show member pathways
11.33 APP CDK5 SOD2
15 11.24 CAV1 HMOX1 MAP3K5 NOS3 PRKAA2 VEGFA
16 11.16 GJA1 HMOX1 NOS3

GO Terms for Ischemia